Product candidate Target indication Development status
ZerenexTM (ferric citrate) Hyperphosphatemia in patients with end-stage renal disease Phase 3 Completed Jan 2013; Pending NDA and MAA submissions.

Japan Phase 3 program completed by sublicensee (JT and Torii); Japanese NDA filed Jan 2013.

ZerenexTM (ferric citrate) Management of serum phosphorus and iron deficiency in anemic patients with Stage 3 to 5 non-dialysis dependent chronic kidney disease ("NDD-CKD") Phase 2 initiated Nov 2012; Ongoing.


Copyright © 2013 by Keryx Biopharmaceuticals, Inc.
Update Notice | Disclaimer | Contact Us